company background image
PMD logo

Psychemedics NasdaqCM:PMD Stock Report

Last Price

US$2.59

Market Cap

US$14.9m

7D

-1.1%

1Y

-46.8%

Updated

28 May, 2024

Data

Company Financials

Psychemedics Corporation

NasdaqCM:PMD Stock Report

Market Cap: US$14.9m

PMD Stock Overview

Engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally.

PMD fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Psychemedics Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Psychemedics
Historical stock prices
Current Share PriceUS$2.59
52 Week HighUS$5.15
52 Week LowUS$2.06
Beta0.72
1 Month Change1.57%
3 Month Change-15.36%
1 Year Change-46.82%
3 Year Change-62.30%
5 Year Change-73.86%
Change since IPO-75.75%

Recent News & Updates

There's Reason For Concern Over Psychemedics Corporation's (NASDAQ:PMD) Massive 28% Price Jump

Jan 08
There's Reason For Concern Over Psychemedics Corporation's (NASDAQ:PMD) Massive 28% Price Jump

Recent updates

There's Reason For Concern Over Psychemedics Corporation's (NASDAQ:PMD) Massive 28% Price Jump

Jan 08
There's Reason For Concern Over Psychemedics Corporation's (NASDAQ:PMD) Massive 28% Price Jump

Psychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07

May 13
Psychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07

Psychemedics GAAP EPS of -$0.06, revenue of $6.51M

Aug 09

Psychemedics: 21% Sales Growth But Net Loss, Takeover Possibility, Covid Recovery Play

Apr 25

Psychemedics: Q3 Revenues +29%, Margins Surge, Possible Corporate Actions Including Dividend

Nov 18

Psychemedics: Market Leader, 8% FCF Yield, Possible Takeover Target

Oct 18

Psychemedics reports Q1 results

May 10

We Think Psychemedics Corporation's (NASDAQ:PMD) CEO Compensation Package Needs To Be Put Under A Microscope

May 07
We Think Psychemedics Corporation's (NASDAQ:PMD) CEO Compensation Package Needs To Be Put Under A Microscope

Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt

Mar 05
Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt

Psychemedics Corp.: Trucking Along Into A Potential Big Catalyst ($21 PT)

Jan 30

How Much Are Psychemedics Corporation (NASDAQ:PMD) Insiders Spending On Buying Shares?

Jan 11
How Much Are Psychemedics Corporation (NASDAQ:PMD) Insiders Spending On Buying Shares?

Psychemedics reports Q3 results

Nov 09

Shareholder Returns

PMDUS HealthcareUS Market
7D-1.1%-2.0%-0.3%
1Y-46.8%5.5%25.6%

Return vs Industry: PMD underperformed the US Healthcare industry which returned 5.5% over the past year.

Return vs Market: PMD underperformed the US Market which returned 25.6% over the past year.

Price Volatility

Is PMD's price volatile compared to industry and market?
PMD volatility
PMD Average Weekly Movement4.6%
Healthcare Industry Average Movement6.4%
Market Average Movement5.9%
10% most volatile stocks in US Market16.0%
10% least volatile stocks in US Market2.8%

Stable Share Price: PMD has not had significant price volatility in the past 3 months.

Volatility Over Time: PMD's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1986116Brian Hullingerwww.psychemedics.com

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company’s testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time.

Psychemedics Corporation Fundamentals Summary

How do Psychemedics's earnings and revenue compare to its market cap?
PMD fundamental statistics
Market capUS$14.92m
Earnings (TTM)-US$4.46m
Revenue (TTM)US$21.60m

0.7x

P/S Ratio

-3.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PMD income statement (TTM)
RevenueUS$21.60m
Cost of RevenueUS$13.27m
Gross ProfitUS$8.33m
Other ExpensesUS$12.79m
Earnings-US$4.46m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.77
Gross Margin38.57%
Net Profit Margin-20.64%
Debt/Equity Ratio3.7%

How did PMD perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.